Business Context and Reporting Period
PolyPid Ltd., a foreign private issuer based in Israel, filed Form 6-K on November 26, 2025. The report covers corporate actions taken during the month of November 2025 regarding its equity financing arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a capital market transaction.
Material Changes
The primary material change reported is the amendment of the company's Sales Agreement with Oppenheimer & Co. Inc., originally dated November 8, 2024. PolyPid Ltd. increased the maximum aggregate offering price of its ordinary shares issuable under this agreement from $8,250,000 to $15,000,000.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or an outlook for future operations. No specific risks or contingencies are detailed in this report, other than the standard legal opinion regarding the legality of the share issuance attached as an exhibit.
Investor Verification Checklist
- Verify the updated maximum aggregate offering price of $15,000,000 under the Sales Agreement with Oppenheimer & Co. Inc.
- Review the legal opinion from Sullivan & Worcester Tel-Aviv (Har-Even & Co.) attached as Exhibit 5.1 regarding the legality of the share issuance.
- Confirm the incorporation of this report by reference into the company's active registration statements on Form F-3 and Form S-8.